Skip to main content
Log in

Nintedanib plus Pirfenidon bei IPF-Patienten

Akzeptable Sicherheit und Verträglichkeit

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

1

Literatur

  1. King TE Jr et al. N Engl J Med. 2014;371(8):783–4

    Google Scholar 

  2. Richeldi L et al. N Engl J Med. 2014;371(8):783

    CAS  PubMed  Google Scholar 

  3. Ogura T et al. Eur Respir J. 2015;45(5):1382–92

    Article  CAS  PubMed  Google Scholar 

  4. Taniguchi et al. Eur Resp J. 2016 (Abstract)

  5. Flaherty KR et al. Am J Respir Crit Care Med. 2017 (Abstract)

  6. Behr J et al. Pneumologie. 2017;71(7):460–74

Originalie

  • Vancheri C, Kreuter M, Richeldi L et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis: Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2017 Sep 10, https://doi.org/10.1164/rccm.201706-1301OC

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Philipp Markart.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markart, P., Günther, A. Akzeptable Sicherheit und Verträglichkeit. Pneumo News 10, 17–18 (2018). https://doi.org/10.1007/s15033-018-0860-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-018-0860-8

Navigation